A new, theoretically safer method of intravitreal injection of bevacizumab in progressive retinopathy of prematurity using scleral trans-illumination

British Journal of Ophthalmology

Volumn 94, Issue 8, 2010, Pages 1107-1109

  Patel, Chetan K ^a   Walker, N J ^a   Kam, J K ^a  

^a OXFORD EYE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

CASE REPORT; DISEASE COURSE; GESTATION PERIOD; HUMAN; ILLUMINATION; LASER COAGULATION; LETTER; NEWBORN; PRIORITY JOURNAL; RETROLENTAL FIBROPLASIA; SCLERA; SCLEROTOMY; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INJECTIONS, INTRAOCULAR; LIGHTING; RETINOPATHY OF PREMATURITY; VITREOUS BODY;

EID: 77955253483     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.162156     Document Type: Letter

References (6)

1. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis 2007;10:133-40.
2. Good W. Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) Randomized Trial. Trans Am Ophthalmol Soc 2004;102:233-50.
3. Kong L, Mintz-Hittner HA, Penland RL, et al. Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol 2008;126:1161-3.
4. Lalwani GA, Berrocal AM, Murray TG, et al. Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 2008;28:S13-18. Erratum in: Retina. 2009;29:127.
5. Streeten BW. The Ciliary Body. In: Tasman W, Jaeger EA, eds. Duanes Clinical Ophthalmology on CD-ROM, 2005 edition. Philadelphia: Lippincott Williams & Wilkins, 2004.
6. Sears JE. Anti-vascular endothelial growth factor and retinopathy of prematurity. Br J Ophthalmol 2008;92:1437-8.